It is increasingly recognized that galactose-deficient IgA in the glomerulus activates the alternative complement system and drives IgA nephropathy, including in the tubules and interstitium, leading ...

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and ...

Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 18, 2026, beginning at ...

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic ...

Fossil fuels will dominate India's energy for 10-15 years, says BPCL's Anurag Saraogi. He states that biofuels will complement, not replace, conventional sources as India makes strides in ethanol ...

Both the Princess of Wales and King Charles have been through cancer diagnoses, with the in-laws able to support one another ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28 ...

For more than a century, tissue biopsies have stood as the gold standard for diagnosing cancer. And for good reason. These ...

IIT Kanpur scientists have unlocked the mystery behind the C5aR2 immune receptor's unique function. Using advanced cryo-EM, ...

Obstetrics and gynecology increasingly intersect with traditional, homeopathic, and alternative medicine as patients seek complementary options across the ...

Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing ...

By the late 20th century, hybrids and alternative fuels like compressed natural gas and propane began reshaping how vehicles ...